Halozyme Therapeutics, Inc. (HALO) has a market capitalization of $7.97B and trades at $67.31. The 52-week range is 47.5-82.22.
Key metrics include a trailing Price-to-Earnings (P/E) ratio of 25.5, Earnings Per Share (EPS) of $2.64, annual revenue of $1.4B.
The stock has a beta of 1.03, operates in the Healthcare sector.
